Abstract

AN NEW THERAPEUTIC REPURPOSING STRATEGIES FOR COVID-19 (SARS CoV 2)

Vijaykumar Andhale* and Dhananjay Landage

ABSTRACT

The severe acute respiratory syndrome Coronavirus 2 i.e. novel corona virus is responsible for formation a disease is known as COVID –19, it become the current health distress emergency to the whole world. Two months ago, world health organization (WHO) declared that COVID-19, is caused by the novel severe respiratory syndrome Coronavirus 2 (SARS – CoV-2). The current COVID-19 emergency demands an urgent development of possible strategies to protect people Covid 19 infection and hence the drug repurposing became an emerging approach to fight COVID-19, this review summarizes an new various therapeutic strategies with special focus on repurposing of drugs to fight against SARS-CoV-2 worldwide. Broad-spectrum antiviral agents (BSAAs) that have believed to be safe through testing on early phase clinical trials. Broad-spectrum antiviral drugs such as Ribavirin, Umifenovir were advised for COVID-19 infection treatment. Some antibiotics may be repurposed as COVID-19 treatments such as oritavancin, dalbavancin, teicoplanin, monensin and azithromycin. Ivermectin an antiparasitic is recently repurposed. Hydroxychloroquine and Chloroquine, having immunomodulating effect in humans, have shown to have antiviral activity at starting and post-entry stages of the SARS-CoV-2 infection. A Novel network-based integrative methodology also used for rapid antiviral drug repurposing against SARS-CoV-2 Virus. This method combines a system pharmacology- based networks drug platform in which quantifies the interaction between host-virus interactome and drug targets in the human Protein-Protein Interactions network.

Keywords: COVID 19, Repurposing of drugs, WHO, Network based drug repurposing, Treatment.